Effect of first-line poly(ADP-ribose) polymerase inhibitor on second-line platinum-based chemotherapy in epithelial ovarian cancer
Journal of Gynecologic Oncology · 2026 · 37 (4)
DOI: 10.3802/jgo.2026.37.e82 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Gynecologic Oncology, 2026. Verfasst von Yusuke Toyohara und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gynecology, The Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan. Hauptthemen laut MEDLINE: Poly(ADP-ribose) Polymerase Inhibitors, Carcinoma, Ovarian Epithelial, Ovarian Neoplasms, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Themen: Onkologische Pflege
Abstract (Originalsprache)
OBJECTIVE: Research on platinum sensitivity after poly(ADP-ribose) polymerase (PARP) inhibitor administration, which offers prognostic benefits for first-line treatment of advanced epithelial ovarian cancer (EOC), is limited. Here, we evaluated the impact of first-line maintenance therapy with PARP inhibitors on the efficacy of second-line platinum-based chemotherapy in patients with advanced EOC. METHODS: We retrospectively analyzed 100 patients with platinum-sensitive recurrent EOC who received second-line platinum-based chemotherapy between 2015 and 2024. The PARP inhibitor group included 35 patients who received PARP inhibitors as first-line maintenance, whereas the control group included 65 patients who did not. Overall response rate, post-recurrence progression-free survival (PFS), and post-recurrence overall survival (OS) were compared between the groups. Subgroup analyses were conducted using homologous recombination deficiency status and platinum-free interval (PFI). RESULTS: The overall response rate was significantly lower in the PARP inhibitor group (25.7%) compared with the control group (89.2%, p
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gynecology, The Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan.
- Department of Gynecology, The Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan. mayu.yunokawa@jfcr.or.jp.
ORCID-Profile: Yusuke Toyohara, Mayu Yunokawa, Ryo Nimura, Eitaro Funada, Risako Ozawa, Kei Kato, Shogo Nishino, Mayumi Kamata, Motoko Kanno, Atsushi Fusegi, Akiko Abe, Sachiho Netsu, Makiko Omi, Yoichi Aoki, Terumi Tanigawa, Sanshiro Okamoto, Hidetaka Nomura, Hiroyuki Kanao
Zitieren
APA
Toyohara, Y., Yunokawa, M., Nimura, R., Funada, E., Ozawa, R., Kato, K., Nishino, S., Kamata, M., Kanno, M., Fusegi, A., Abe, A., Netsu, S., Omi, M., Aoki, Y., Tanigawa, T., Okamoto, S., Nomura, H., & Kanao, H. (2026). Effect of first-line poly(ADP-ribose) polymerase inhibitor on second-line platinum-based chemotherapy in epithelial ovarian cancer. Journal of Gynecologic Oncology, 37(4). https://doi.org/10.3802/jgo.2026.37.e82
Vancouver
Toyohara Y, Yunokawa M, Nimura R, Funada E, Ozawa R, Kato K, et al. Effect of first-line poly(ADP-ribose) polymerase inhibitor on second-line platinum-based chemotherapy in epithelial ovarian cancer. Journal of Gynecologic Oncology. 2026;37(4). doi:10.3802/jgo.2026.37.e82
BibTeX
@article{Toyohara2026,
author = {Toyohara, Yusuke and Yunokawa, Mayu and Nimura, Ryo and Funada, Eitaro and Ozawa, Risako and Kato, Kei and Nishino, Shogo and Kamata, Mayumi and Kanno, Motoko and Fusegi, Atsushi and Abe, Akiko and Netsu, Sachiho and Omi, Makiko and Aoki, Yoichi and Tanigawa, Terumi and Okamoto, Sanshiro and Nomura, Hidetaka and Kanao, Hiroyuki},
title = {Effect of first-line poly(ADP-ribose) polymerase inhibitor on second-line platinum-based chemotherapy in epithelial ovarian cancer},
journal = {Journal of Gynecologic Oncology},
year = {2026},
volume = {37},
number = {4},
doi = {10.3802/jgo.2026.37.e82}
}
EUVIMED